The childhood vaccine schedule underwent significant changes recently, with the Department of Health and Human Services (HHS) reducing the number of universally recommended vaccines from 17 to 11. Amidst these adjustments, guidance regarding the human papillomavirus (HPV) vaccine has shifted, suggesting that a single dose may be sufficient for protection—a change that reflects evolving research on the vaccine’s effectiveness. This potential simplification of the HPV vaccination schedule could have broad implications for public health, particularly in increasing vaccine uptake and accessibility. The question of whether one shot of the HPV vaccine is enough is now at the forefront of discussions among medical professionals and public health officials.
For years, the HPV vaccine was administered in a three-dose regimen, spaced out over several months. As research progressed, evidence emerged suggesting that two doses provided comparable protection, leading the World Health Organization, the Advisory Committee on Immunization Practices (ACIP), and the Centers for Disease Control and Prevention (CDC) to recommend a two-dose schedule for most young people. Now, the newest data indicates that even a single dose could offer substantial immunity. This evolving understanding of the HPV vaccine’s efficacy is driving the current reevaluation of vaccination protocols.
The ESCUDDO Trial: Evidence for Single-Dose Effectiveness
The impetus for considering a single-dose HPV vaccine schedule stems largely from the ESCUDDO trial, a research study conducted in Costa Rica and published in the Novel England Journal of Medicine in December 2025. The trial enrolled over 20,000 girls aged 12-16 beginning in 2017, randomly assigning them to one of four groups to compare the effectiveness of different vaccination strategies.
- The first group received one dose of Cervarix, a vaccine protecting against HPV types 16 and 18, responsible for approximately 70% of cervical cancers.
- The second group received two doses of Cervarix. (Cervarix is no longer available in the United States but remains in use internationally.)
- The third group received one dose of Gardasil 9, which protects against nine HPV types linked to cancer and genital warts.
- The fourth group received two doses of Gardasil 9, currently the only HPV vaccine available in the United States.
The results were striking: all four groups demonstrated over 97% effectiveness. Researchers concluded that a single dose of either vaccine was as effective as two doses in protecting against HPV types 16 and 18. Gardasil 9’s broader protection extends to seven additional HPV types associated with genital warts and other cancers, including cancers of the penis, vulva, anus, and throat. A similar randomized trial conducted in Kenya also found that one dose of Gardasil 9 or Cervarix was 98% effective in preventing HPV 16 and 18.
Potential Benefits and Concerns
The potential shift to a single-dose HPV vaccine schedule offers several advantages. It could significantly increase vaccine uptake by removing barriers related to transportation and time commitments, making it easier for individuals to complete the vaccination series. This simplification would also reduce costs and logistical challenges, particularly in low-resource countries where large-scale vaccination campaigns are crucial.
However, the change has not been without controversy. The American Academy of Pediatrics (AAP) has not yet updated its recommendations, a decision that has raised concerns about potential confusion among healthcare providers and parents. Many physicians rely on AAP guidance when making vaccination decisions for their patients. Some experts have expressed concern over the process by which HHS made this change, noting that it occurred “behind closed doors” without the usual public comment period afforded to changes made by an advisory committee. Some of the other changes to the vaccine schedule announced at the same time were also not based on science, adding to the unease.
Navigating Conflicting Recommendations
The discrepancy between the HHS guidance and the AAP’s continued recommendation for two doses highlights the complexities of translating research into clinical practice. While the scientific evidence supporting a single-dose regimen is growing, the AAP’s cautious approach reflects a desire to ensure the highest level of protection for patients. This situation underscores the importance of open communication between parents and their pediatricians to determine the most appropriate vaccination strategy for their children.
Experts suggest that parents should consult with their pediatrician for personalized advice on which vaccines—and how many doses—will best protect their children. The evolving landscape of vaccine recommendations requires a collaborative approach between healthcare providers and families to ensure informed decision-making.
Disclaimer: This article provides general information about the HPV vaccine and should not be considered medical advice. Please consult with a qualified healthcare professional for personalized guidance on vaccination decisions.
The CDC and HHS are expected to provide further clarification on the new vaccine schedule and address concerns raised by the AAP in the coming months. Parents and healthcare providers should stay informed about these updates to ensure they are following the most current recommendations. The ongoing evaluation of vaccine schedules is a testament to the commitment to protecting public health through evidence-based practices.
What are your thoughts on the changing HPV vaccine recommendations? Share your comments below, and please share this article with your network.
